tiprankstipranks
Blurbs

Maxim Group Sticks to Its Buy Rating for Neurosense Therapeutics Ltd. (NRSN)

Maxim Group analyst Naz Rahman maintained a Buy rating on Neurosense Therapeutics Ltd. (NRSNResearch Report) yesterday and set a price target of $7.00. The company’s shares opened today at $1.79.

According to TipRanks, Rahman is an analyst with an average return of -16.2% and a 30.11% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Processa Pharmaceuticals, Agile Therapeutics, and Amryt Pharma.

Neurosense Therapeutics Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.

See the top stocks recommended by analysts >>

NRSN market cap is currently $14.71M and has a P/E ratio of -1.07.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Read More on NRSN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles